Form 4: Regeneron CEO Schleifer Reports Stock Transactions

Regeneron Pharmaceuticals' Co-Chair, President & CEO, Leonard S. Schleifer, reported the vesting of performance stock units and related stock transactions.

Summary

• Leonard S. Schleifer, Co-Chair, President & CEO of Regeneron Pharmaceuticals, Inc. (REGN), reported changes in his beneficial ownership of common stock.
• On December 31, 2025, 28,570 performance restricted stock units (PSUs) vested, representing a contingent right to receive one share of Company stock for each PSU.
• These PSUs were earned during an applicable five-year performance period and vested at a price of $0.0 per unit.
• Concurrently, 28,570 shares of common stock were disposed of at a price of $772.09 per share, likely for tax withholding purposes related to the PSU vesting.
• Following these transactions, Mr. Schleifer directly owns 214,523 shares of common stock.
• Indirect beneficial ownership includes 127,484 shares via a 2024 GRAT, 300,000 shares via a 2025 GRAT, 5,989 shares via a 401(k) Plan, and 39,985 shares via a Trust.
• Mr. Schleifer also directly holds 595,077 derivative securities, specifically 2020 Performance Stock Units.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction involving the vesting of performance-based equity awards and a corresponding disposition for tax purposes. This is a neutral event that reflects standard executive compensation practices and does not provide new information to significantly alter the company's fundamental outlook or sentiment.

Positives

• The vesting of 28,570 performance restricted stock units indicates that performance targets set for the five-year period were met, aligning executive compensation with company performance.

Negatives

• A disposition of 28,570 shares of common stock occurred at $772.09 per share, likely for tax withholding, which reduces the direct beneficial ownership of the executive.

Risks

• The vested performance restricted stock units are subject to a mandatory holding period of three years after vesting, which could limit the reporting person's liquidity for these shares, though this period ends early upon death, disability, or a change in control of the Company.

Future Outlook

The vested performance restricted stock units are subject to a mandatory holding period of three years after vesting, which will conclude on December 31, 2028, unless an earlier event such as death, disability, or a change in control of the Company occurs.

Industry Context

This filing represents a routine insider transaction related to executive compensation, specifically the vesting of performance-based equity awards. Such compensation structures are common in the pharmaceutical industry to align executive incentives with long-term company performance and shareholder value.

Comparison to Industry Standards

• The use of Performance Stock Units (PSUs) as a component of executive compensation is a standard practice across the pharmaceutical and broader corporate sectors, aligning executive interests with company performance over multi-year periods.
• The disposition of shares to cover tax obligations upon vesting is also a common and expected event for equity awards, consistent with practices observed at comparable companies like Pfizer, Merck, or Johnson & Johnson when their executives' restricted stock or PSUs vest.

Stakeholder Impact

• Shareholders: The vesting of PSUs demonstrates executive alignment with shareholder interests through performance-based compensation. The subsequent sale for tax purposes is a routine event and does not indicate a change in the executive's long-term commitment.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The mandatory three-year holding period for the vested shares will continue until December 31, 2028, unless specific conditions for early termination are met.

Key Dates

Recommendation

This Form 4 reports a routine vesting of performance stock units and a corresponding disposition for tax withholding by a key executive. It does not provide new fundamental information regarding the company's operations, financial performance, or strategic direction that would warrant a change in an existing investment thesis. Therefore, a 'hold' recommendation is maintained, pending further operational or financial updates.

Keywords

Regeneron Pharmaceuticals, REGN, Leonard S. Schleifer, Form 4, Insider Trading, Performance Stock Units, PSU Vesting, Executive Compensation, Beneficial Ownership